SCHEMBL29168362

SCHEMBL29168362

COC(=O)C1CCC(n2ccc3[nH]ncc3c2=O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ PIK3CD O00329 3/20 0.35
▸ PIM1 P11309 3/20 0.35
▸ PIK3CA P42336 3/20 0.35
▸ GSK3B P49841 3/20 0.35
▸ PIK3CG P48736 2/20 0.35
▸ PIK3CB P42338 2/20 0.35
▸ ABL1 P00519 2/20 0.34
▸ PDE3B Q13370 1/20 0.34
▸ PDE3A Q14432 1/20 0.34
▸ IDO1 P14902 1/20 0.34
▸ TNKS O95271 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27186122 0.85 PIK3CD (0.38) MAP4K1PIK3CDPIM1PIK3CAGSK3B
SCHEMBL27186117 0.85 PIK3CD (0.38) MAP4K1PIK3CDPIM1PIK3CAGSK3B
Hydrochloric Acid SCHEMBL28431833 0.84 METAP2 (0.36) KDM4EHSD17B10ALDH1A1IDO1TNKS
SCHEMBL27186139 0.76 HCAR1 (0.39) MAP4K1PIK3CDPIK3CAGSK3BPIK3CG
SCHEMBL27186487 0.74 JAK1 (0.43) MAP4K1PIK3CDPIK3CAIDO1
SCHEMBL7395636 0.72 ALDH1A1 (0.39) KDM4EHSD17B10ALDH1A1PDE3BPDE3A
SCHEMBL27186077 0.71 MAP4K1 (0.32) MAP4K1
SCHEMBL25379016 0.70 SMN1; SMN2 (0.38) KDM4EHPGDHSD17B10ALDH1A1PKM
SCHEMBL30442517 0.70 SMN1; SMN2 (0.38) KDM4EHPGDHSD17B10ALDH1A1PKM
SCHEMBL29844145 0.70 SMN1; SMN2 (0.38) HPGDHSD17B10ALDH1A1PKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 — — US disclosed
CN-117651701-A Novel substituted bicyclic aza heterocycles as SOS1 inhibitors 唯久生物技术(苏州)有限公司 2024-03-05 — — CN disclosed
WO-2022187266-A1 NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 MAP4K1 632/4885KDM4E 1518/4885HPGD 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback